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BACKGROUND. The American Cancer Society, the Centers for Disease Control and Prevention (CDC), the National
Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) collaborate annu-
ally to provide updated information regarding cancer occurrence and trends in the United States. This year’s report
includes trends in colorectal cancer (CRC) incidence and death rates and highlights the use of microsimulation mod-
eling as a tool for interpreting past trends and projecting future trends to assist in cancer control planning and policy
decisions. METHODS. Information regarding invasive cancers was obtained from the NCI, CDC, and NAACCR; and in-
formation on deaths was obtained from the CDC’s National Center for Health Statistics. Annual percentage changes
in the age-standardized incidence and death rates (based on the year 2000 US population standard) for all cancers
combined and for the top 15 cancers were estimated by joinpoint analysis of long-term trends (1975-2006) and for
short-term fixed-interval trends (1997-2006). All statistical tests were 2-sided. RESULTS. Both incidence and death
rates from all cancers combined significantly declined (P < .05) in the most recent time period for men and women
overall and for most racial and ethnic populations. These decreases were driven largely by declines in both incidence
and death rates for the 3 most common cancers in men (ie, lung and prostate cancers and CRC) and for 2 of the 3
leading cancers in women (ie, breast cancer and CRC). The long-term trends for lung cancer mortality in women had
smaller and smaller increases until 2003, when there was a change to a nonsignificant decline. Microsimulation mod-
eling demonstrates that declines in CRC death rates are consistent with a relatively large contribution from screening
and with a smaller but demonstrable impact of risk factor reductions and improved treatments. These declines are
projected to continue if risk factor modification, screening, and treatment remain at current rates, but they could be
accelerated further with favorable trends in risk factors and higher utilization of screening and optimal treatment.
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Commentary
CONCLUSIONS. Although the decrease in overall cancer incidence and death rates is encouraging, rising incidence
and mortality for some cancers are of concern. Cancer 2010;116:544–73. VC 2009 American Cancer Society.
KEYWORDS: cancer, incidence, mortality, Surveillance, Epidemiology, and End Results, North American Association
of Central Cancer Registries, National Program of Cancer Registries, United States, Cancer Intervention and
Surveillance Modeling Network colon models, microsimulation models, colorectal cancer.
The American Cancer Society (ACS), the Centers for
Disease Control and Prevention (CDC), the National
Cancer Institute (NCI), and the North American Associa-
tion of Central Cancer Registries (NAACCR) collaborate
each year to produce a report to the nation on the current
status of cancer in the United States. The first report, pub-
lished in 1998, documented the first sustained decline in
cancer death rates since the 1930s.1 Subsequent reports
have updated information on trends in incidence and
death rates and featured in-depth analyses of selected
topics,2-10 including incidence and mortality trends for
colorectal cancer (CRC).11 The current report provides
updated trends in incidence and death rates for all cancers
combined and for the top 15 cancers among all races com-
bined and among each of the 5 major racial/ethnic groups
(white, black, Asian and Pacific Islander [API], American
Indian/Alaska Natives [AI/AN], and Hispanic) by sex; it
also provides incidence and mortality data for AI/AN who
reside in counties covered by the Indian Health Service
(IHS) Contract Health Services Delivery Area (CHSDA).
Furthermore, this report provides an update on incidence
and mortality trends for CRC and uses a microsimulation
model of CRC to interpret past trends and project future
trends. Our application of simulation modeling provides
information on the relative impact of modifiable risk fac-
tors, screening use, and treatment patterns on cancer
trends and compares different future scenarios. The meth-
odology did not focus on applications comparing multi-
ple strategies for a category of interventions (eg, screening
tests) nor multiple types of models. The report also high-
lights the use of microsimulation models to assist in can-
cer prevention and control planning and in setting public
policy (available at: http://cisnet.cancer.gov/projections/
colorectal/ accessed on September 30, 2009).
MATERIALS AND METHODS
Cancers, Cancer Deaths, and Population
Estimates
Information on newly diagnosed invasive cancers, includ-
ing in situ cancers of the bladder, was obtained from pop-
ulation-based cancer registries that participate in the
NCI’s Surveillance, Epidemiology, and End Results
(SEER) Program and/or the CDC’s National Program of
Cancer Registries (NPCR). All participating cancer regis-
tries are members of the NAACCR.
Site and histology for incidence cancers were coded
according to the International Classification of Diseases
(ICD) for Oncology (ICD-O) edition in use at the time
of diagnosis, converted to the third edition coding,12 and
categorized according to SEER site groups.13 For cancer
deaths, the underlying causes of death were selected
according to the version of the ICD codes and selection
rules in use at the time of death (ICD-6 through ICD-
10).14-18
Cause of death is based on death certificate informa-
tion reported to state vital statistics offices; this informa-
tion is consolidated through the CDC National Center
for Health Statistics (NCHS) National Vital Statistics
System19 and categorized according to SEER anatomic
site groups13 to maximize comparability among ICD and
ICD-O versions. County-level population estimates,
summed to the state and national level, were used as
denominators in rate calculations.20 Because the 2000 US
census allowed respondents to identify themselves as mul-
tiracial, the NCHS and the Census Bureau developed
methods for bridging multiple-race population estimates
to single-race estimates to describe long-term trends in
disease rates by race.21 The Census Bureau has provided
NCI with bridged, single-race annual population esti-
mates from 1990-2007 with annual re-estimates calcu-
lated back to the most recent decennial census. NCI
makes slight modifications to the Hawaii population esti-
mates based on additional local information (available
at: http://seer.cancer.gov/popdata/methods.html accessed
on August 21, 2009).
For most states, population estimates as of July 1 of
each year were used to calculate annual incidence and
death rates, because these estimates are presumed to reflect
the average population of a defined geographic area for a
calendar year. For Louisiana, Alabama, Mississippi, and
Texas, where residents were displaced in the fall of 2005
by hurricanes Katrina and Rita, incidence data for the first
6 months of 2005 and half of the July 1 population
2009 Report on the Status of Cancer/Edwards et al
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estimate were used to calculate state-specific incidence
rates for 2005. For the 2005 death rate calculations, the
NCI made adjustments to the 2005 population estimates
to account for the displacement, and these data
were made available for use by the cancer surveillance
agencies. The national total population estimates are not
affected by these adjustments. Further details on these cal-
culations are provided at http://seer.cancer.gov/popdata/
methods.html (accessed on August 21, 2009).
Incidence data are not available uniformly for every
period, geographic area, or racial and ethnic group in the
United States. Therefore, analyses of long-term (1975-
2006) and short-term fixed-interval (1997-2006) trends
in incidence rates and in 5-year (2002-2006) average age-
standardized incidence rates for the top 15 cancer sites
include different geographic areas and populations. To
evaluate the long-term incidence trends (1975-2006) for
all races and ethnicities combined, data were used from
the 9 original SEER areas (Atlanta, Connecticut, Detroit,
Hawaii, Iowa, New Mexico, San Francisco-Oakland,
Seattle-Puget Sound, and Utah), which cover approxi-
mately 10% of the US population (9% each of US whites
and US blacks, 8% of US Hispanics, and 19% of US
Asians).22 Data from 33 population-based cancer regis-
tries were used to assess short-term trends (1997-2006),
and data from 43 population-based cancer registries were
used to estimate 5-year average annual (2002-2006), age-
standardized incidence rates for all races and ethnicities
combined and for each of the 5 major racial/ethnic popu-
lations (white, black, API, AI/AN residing in counties
covered by the IHS CHSDA, and Hispanic). The 33 and
43 registries met NAACCR’s data-quality criteria for ev-
ery year that was included in the analysis; these registries
cover approximately 71% and 86% of the US population,
respectively. The 33 cancer registries cover 71% of the US
white population, 63% of the US black population, 88%
of the USHispanic population, 87% of the US API popu-
lation, and 72% of the AI/AN (CHSDA) population; the
43 cancer registries cover 86% of the US white popula-
tion, 83% of the US black population, 92% of the US
Hispanic population, 93% of the US API population, and
78% of the US AI/AN (CHSDA) population. New inci-
dence cases identified through the IHS were incorporated
into the pooled cancer registry analysis file.9
US mortality data from NCHS were unavailable for
every racial/ethnic group for all periods studied; notably,
the Hispanic ethnicity was not reported on death certifi-
cates in every state for all years during the period 1997-
2006. For all races and ethnicities combined, we examined
long-term (1975-2006) trends, short-term (1997-2006)
trends, and 5-year (2002-2006) average annual age-stand-
ardized death rates for all cancer sites and for the top 15
cancer sites for men and women in each of the 5 major
racial/ethnic populations (white, black, API, AI/AN
CHSDA, and Hispanic). Mortality data for the AI/AN
population were based on deaths in counties served by
IHS’s CHSDA, because estimated rates based on CHSDA
counties reportedly are more reliable than national data.9
Statistical Analysis
Age-specific and age-standardized rates were expressed per
100,000 population (based on the year 2000 US standard
population) and were generated by using SEER*Stat Soft-
ware, version 6.5.2 (available at: http://www.seer.cancer.
gov/seerstat23 and http://seer.cancer.gov/popdata/methods.
html accessed on August 21, 2009). Rates for 2002-2006
were suppressed if the numerator was <16 observations,
consistent with our previous work.6-10
Long-term trends (1975-2006) in age-standardized
SEER 9 cancer incidence and US death rates were
described using joinpoint regression analysis, which
involves fitting a series of joined straight lines on a logarith-
mic scale to the trends in the annual age-standardized rates
(available at: http://seer.cancer.gov/csr/1975_2006/tech-
notes/joinpoint.html accessed on September 15, 2009).
We allowed a maximum of 4 joinpoints in the model to
better characterize emerging trends, which are expressed in
up to 5 variable time intervals. The method is described in
detail elsewhere.24 The resulting trends of various time
periods are described by the annual percent change (APC)
(ie, the slope of the line segment).24 Long-term incidence
trends are based on both observed data and data adjusted
for reporting delay (which mostly affects recent years).25
Our descriptions of long-term trends in incidence are based
on the delay-adjusted data except when specifically noted.
For short-term, fixed-interval (1997-2006) trend analyses,
a joinpoint regression analysis with a maximum of 1 join-
point was used to estimate APCs.
This year’s report provides the average APC (AAPC)
as an addendum to the underlying joinpoint trends and as
a summary measure to compare fixed-interval trends by
race/ethnicity. The AAPC quantifies the average trend over
a period of multiple years. It can be estimated even if the
joinpoint model indicates that changes in trends occurred
during those years, because the AAPC is estimated as a geo-
metric weighted average of the joinpoint APCs, with the
weights equal to the lengths of each segment over the
Commentary
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prespecified fixed interval (available at: http://srab.cancer.
gov/joinpoint/aapc.html accessed on September 15,
2009).26,27 The APC was suppressed if the numerator was
<10 cancers for any year within the designated time inter-
val, consistent with our previous methods.6-10
In describing long-term and short-term trends with
estimates of APC and AAPC, the terms ‘‘increase’’ and
‘‘decrease’’ were used when the slope (APC or AAPC) of
the trend was statistically significant (P < .05). When the
trend was not significant, terms such as ‘‘level,’’ ‘‘stable,’’
‘‘nonsignificant increase,’’ and ‘‘nonsignificant decrease’’
were used, depending on the results.
CRC Rates and Trends
Age-standardized CRC incidence rates for diagnosis years
2002-2006 and AAPC estimates of short-term trends for
diagnosis years 1997-2006 were based on SEER and
NPCR pooled data reported by the NAACCR. For diag-
nosis years 2002-2006, we also present 5-year average age-
specific CRC incidence rates for groups aged <50 years,
aged 50-64 years, and aged 65 years; for colorectal sub-
sites (proximal colon, distal colon, rectum, and other); for
racial/ethnic groups (white, black, API, AI/AN CHSDA,
Hispanic, and non-Hispanic); and for combinations of
these variables. Anatomic subsite was based on the ICD-O-
3 codes for broad categories: proximal colon (codes C18.0
and C18.2-C18.5), distal colon (codes C18.6 and C18.7),
rectum (codes C19.9 and C20.9), and other (codes C18.1,
C18.8, C18.9, and C26.0). Changes in coding rules for
stage of cancer at diagnosis, particularly introduction of the
Collaborative Stage (CS)Data Collection System (available
at: http://training.seer.cancer.gov/collaborative accessed on
September 30, 2009) for cases diagnosed in 2004 forward,
caused a systematic shift in stage between 2003 and 2004
and, thus, precluded the use of NAACCR pooled data to
evaluate stage-specific cancer incidence trends. Stage-spe-
cific analyses were based on the SEER Extent of Disease
codes and CS for the SEER 9 registries (available at: http://
seer.cancer.gov accessed on September 30, 2009). Long-
term trends in stage-specific incidence rates and 5-year
stage-specific relative survival for CRC used the SEER 9
data for diagnosis years 1975-2006, based on historic stage
(localized, regional, distant, and unknown).
CRC Incidence and Mortality Models:
Assessing the Impact of Risk Factors,
Screening, and Treatment
We used a microsimulation model,28 microsimulation
screening analysis (MISCAN-Colon), from NCI’s Cancer
Intervention and Surveillance Modeling Network (CIS-
NET) consortium (available at: http://cisnet.cancer.gov/
projections/colorectal accessed on September 30, 2009)
to estimate the impact of historic changes in risk factors,
screening, and treatment on past CRC incidence and
mortality trends and to project future mortality trends
through 2020. The projections of future mortality trends
have been published previously, whereas the past trends
are an intermediate result of this previously published
work. Consequently, the model methodology, inputs,
and assumptions have been described previously.29-31
Briefly, the MISCAN-Colon model simulates the US
population from 1975 to 2020 based on the sequence of
developments as an adenoma becomes cancer.32-34 The
model also distinguishes 3 types of interventions that are
considered separately and as combined interventions that
can affect the natural history of the adenoma-carcinoma
sequence (Fig. 1).29,35,36 MISCAN-Colon models the
influence of risk factors through changing the risk of
developing adenomas. Screening is modeled as potentially
affecting adenomas, preclinical disease, and clinical dis-
ease (the effect depends on the screening test).
The MISCAN-Colon model includes risk factors
that can increase risk for CRC (eg, smoking, obesity, and
red meat consumption) and factors that may decrease risk
for CRC (eg, aspirin use, multivitamin use [including
supplemental folate and calcium], and physical activity).
Wemodeled the impact of the risk factors by using the rel-
ative risk for adenomas associated with each factor in con-
junction with the prevalence of the factor over time in the
population, as described previously29 (available at: http://
cisnet.cancer.gov/projections/colorectal accessed on Sep-
tember 30, 2009). Prevalence rates were obtained primar-
ily from the Cancer Progress Report.37 We assumed a
smoking rate of 42% in 1965, 23% in 2000, and a pro-
jected rate of 11% to 17% in 2020, depending on the
future scenario. We assumed an obesity rate of 13% in
1965, 31% in 2000, and a projected rate of 34% to 45%
in 2020. For CRC screening uptake, we used National
Health Interview Survey (NHIS)38 data from 1987,
1992, 1998, and 2000 to estimate screening test rates for
fecal occult blood testing (FOBT) for individuals aged
50 years who have had an FOBT within past 2 years and
endoscopy (including flexible sigmoidoscopy and colono-
scopy) for individuals aged50 years who have had a sig-
moidoscopy or colonoscopy (collectively known as
endoscopy) at some point in their life, by 5-year age
groups, and applied both screening rates and the sensitiv-
ity and specificity of each screening test to the model.
CRC screening rates by 5-year age groups were calculated
2009 Report on the Status of Cancer/Edwards et al
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separately for home-based FOBT and endoscopy (includ-
ing flexible sigmoidoscopy and colonoscopy). The NHIS
did not distinguish between home-based FOBT and
office-based FOBT or the type of endoscopy before the
2000 survey. Because office-based FOBT is not an effec-
tive method for CRC screening,39 the proportion of
home-based FOBT in 2000 was applied to the earlier
years of data to calculate FOBT prevalence. Similarly,
the proportions of endoscopies that were sigmoidoscop-
ies and colonoscopies were derived from the 2000 data
and applied to earlier years. For 2000, we assumed a
CRC screening rate of 24% with FOBT and 39% for en-
doscopy and a projected increase in screening rates in
2020, with an FOBT prevalence of 35% to 38% and an
endoscopy prevalence of 56% to 61% (see Supporting
Information Table 1; available at: www.seer.cancer.gov/
report_to_nation/1975-2006). We assumed no CRC
screening before 1978.
To assess the effects of treatment, the model distin-
guished 4 chemotherapy regimens for stage III-IV CRC,
depending on the treatment available to US patients diag-
nosed in different periods. These regimens were 1) 5-fluo-
rouracil (5-FU) (available before 1996); 2) 5-fluorouracil
and irinotecan (available 1996-2001); 3) 5-FU, irinote-
can, and oxaliplatin (2002-2003); and 4) 5-FU, irinote-
can, oxaliplatin, and bevacizumab/cetuximab (2004 and
afterward). Hazard ratios for disease-free survival were
obtained from published clinical trials for each of the
treatment regimens40-52 and were applied to the 1975
through 1979 stage-specific relative survival rates from
SEER 9. Chemotherapy use by age and time for the US
population were based on the SEER-Medicare linked
database,53 survey data, and patterns of care studies.54,55
We assumed increasing CRC treatment rates over time,
with a projected rate of 8% in 2005 and that, by 2020,
45% to 83% of patients with CRC would be treated with
combination therapy, including 5-FU, irinotecan, oxali-
platin, and biologics.
The key long-term outcomes measured in the MIS-
CAN-Colon model are the changes in CRC incidence and
death rates as a result of the changes in risk factors, screen-
ing, and treatment in past and future time periods. To pro-
ject future trends,29 we considered 3 hypothetical
scenarios, including frozen trends (risk factor, screening,
and treatment rates plateau at year 2000), continued trends
(risk factor, screening, and treatment rates continue to
increase annually at the current rate), and optimistic trends,
in which all 3 interventions of risk factors, screening, and
treatment improved at a rate that was considered optimistic
but realistic.29 The prevalence assumptions of these factors
from 1965 to 2000, as observed, and from 2000 to 2020,
as projected under each scenario, are presented online
Figure 1. This is a graphic representation of the adenoma-carcinoma sequence in the microsimulation screening analysis
(MISCAN-Colon) model and potential interventions that affect the natural history of disease. The natural history of colorectal can-
cer is depicted from adenoma to carcinoma. An individual can develop 1 or more adenomas, which can increase in size. Some
adenomas will become invasive cancers, which initially are preclinical and then become clinical. The opportunity to intervene in
the natural history through risk factors, screening, and treatment is noted.
Commentary
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Table 1. Surveillance, Epidemiology, and End Results Cancer Incidence Rate Trends With Joinpoint Analyses for
1975-2006 for the Top 15 Cancers, by Sex, for All Racesa
Joinpoint Analyses (1975-2006)b
Trend 1 Trend 2 Trend 3 Trend 4 Trend 5 AAPCf
Sex/Cancer Site or Type Years APCe Years APCe Years APCe Years APCe Years APCe 1997-
2006
2002-
2006
All sitesc
Both sexes 1975-1989 1.2g 1989-1992 2.8g 1992-1995 2.4 1995-1999 1.0 1999-2006 1.1g 0.6h 1.1h
(Delay-adjusted) 1975-1989 1.2g 1989-1992 2.8 1992-1995 2.4 1995-1999 0.9 1999-2006 0.7g 0.4h 0.7h
Males 1975-1989 1.3g 1989-1992 5.1g 1992-1995 4.8g 1995-2001 0.3 2001-2006 1.9g 0.9h 1.9h
(Delay-adjusted) 1975-1989 1.3g 1989-1992 5.2g 1992-1995 4.9g 1995-2000 0.5 2000-2006 1.3g 0.7h 1.3h
Females 1975-1979 0.3 1979-1987 1.6g 1987-1995 0.1 1995-1998 1.5 1998-2006 0.8g 0.5h 0.8h
(Delay-adjusted) 1975-1979 0.3 1979-1987 1.6g 1987-1995 0.1 1995-1998 1.4 1998-2006 0.5g 0.3 0.5h
Top 15 cancers for malesd
Prostate 1975-1988 2.6g 1988-1992 16.4g 1992-1995 11.4g 1995-2001 1.8 2001-2006 3.4g 1.1 3.4h
(Delay-adjusted) 1975-1988 2.6g 1988-1992 16.5g 1992-1995 11.7g 1995-2000 2.4 2000-2006 2.4g 0.8 2.4h
Lung and bronchus 1975-1982 1.4g 1982-1991 0.4 1991-2006 1.9g 1.9h 1.9h
(Delay-adjusted) 1975-1982 1.4g 1982-1991 0.4 1991-2006 1.8g 1.8h 1.8h
Colon and rectum 1975-1986 1.1g 1986-1995 2.1g 1995-1998 1.1 1998-2004 2.6g 2004-2006 5.7g 2.9h 4.2h
(Delay-adjusted) 1975-1985 1.1g 1985-1991 1.2g 1991-1995 3.2g 1995-1998 2.1 1998-2006 3.0g 2.5h 3.0h
Urinary bladder 1975-1987 1.0g 1987-1996 0.5 1996-1999 1.8 1999-2006 0.8g 0.2 0.8h
(Delay-adjusted) 1975-1987 0.9g 1987-2006 0.0 0.0 0.0
Melanoma of the skin 1975-1986 5.5g 1986-2006 2.9g 2.9h 2.9h
(Delay-adjusted) 1975-1986 5.4g 1986-2006 3.1g 3.1h 3.1h
Non-Hodgkin lymphoma 1975-1991 4.3g 1991-2006 0.1 0.1 0.1
(Delay-adjusted) 1975-1991 4.2g 1991-2006 0.3 0.3 0.3
Kidney and renal pelvis 1975-2006 1.7g 1.7h 1.7h
(Delay-adjusted) 1975-2006 1.8g 1.8h 1.8h
Leukemia 1975-2004 0.1 2004-2006 6.6 1.6h 3.4
(Delay-adjusted) 1975-2006 0.1g 0.1h 0.1h
Oral cavity and pharynx 1975-1983 0.2 1983-2006 1.4g 1.4h 1.4h
(Delay-adjusted) 1975-2006 1.2g 1.2h 1.2h
Pancreas 1975-1993 0.9g 1993-2006 0.3 0.3 0.3
(Delay-adjusted) 1975-1981 1.8g 1981-1985 1.1 1985-1990 2.1 1990-2003 0.1 2003-2006 2.5 0.9 1.9
Stomach 1975-1988 1.2g 1988-2006 2.0g 2.0h 2.0h
(Delay-adjusted) 1975-1988 1.2g 1988-2006 2.0g 2.0h 2.0h
Liver and intrahepatic
bile duct
1975-1986 2.1g 1986-1996 4.9g 1996-2006 2.6g 2.6h 2.6h
(Delay-adjusted) 1975-2006 3.6g 3.6h 3.6h
Esophagus 1975-2006 0.7g 0.7h 0.7h
(Delay-adjusted) 1975-2006 0.7g 0.7h 0.7h
Brain and other
nervous system
1975-1991 1.1g 1991-2006 0.7g 0.7h 0.7h
(Delay-adjusted) 1975-1991 1.0g 1991-2006 0.5g 0.5h 0.5h
Myeloma 1975-2002 0.8g 2002-2006 3.0 0.9 3.0
(Delay-adjusted) 1975-2006 0.7g 0.7h 0.7h
Top 15 cancers for femalesd
Breast 1975-1980 0.5 1980-1987 4.0g 1987-1994 0.2 1994-1999 1.6g 1999-2006 2.2g 1.3h 2.2h
(Delay-adjusted) 1975-1980 0.5 1980-1987 4.0g 1987-1994 0.1 1994-1999 1.6g 1999-2006 2.0g 1.2h 2.0h
Lung and bronchus 1975-1982 5.5g 1982-1990 3.5g 1990-1998 1.0g 1998-2006 0.1 0.0 0.1
(Delay-adjusted) 1975-1982 5.6g 1982-1991 3.4g 1991-2006 0.4g 0.4h 0.4h
Colon and rectum 1975-1985 0.3 1985-1995 1.9g 1995-1998 2.0 1998-2006 2.4g 1.9h 2.4h
(Delay-adjusted) 1975-1985 0.3 1985-1995 1.8g 1995-1998 1.9 1998-2006 2.2g 1.7h 2.2h
Corpus and uterus, NOS 1975-1979 6.0g 1979-1988 1.7g 1988-1997 0.7g 1997-2006 0.6g 0.6h 0.6h
(Delay-adjusted) 1975-1979 6.0g 1979-1988 1.7g 1988-1997 0.7g 1997-2006 0.5g 0.5g 0.5h
Melanoma of the skin 1975-1980 5.6g 1980-2006 2.4g 2.4h 2.4h
(Delay-adjusted) 1975-1981 5.7g 1981-1993 1.9g 1993-2006 3.0g 3.0h 3.0h
Non-Hodgkin lymphoma 1975-1990 2.8g 1990-2004 1.2g 2004-2006 2.5 0.3 0.7
(Delay-adjusted) 1975-1990 2.9g 1990-2006 1.1g 1.1h 1.1h
(Continued)
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at www.seer.cancer.gov/report_to_nation/1975-2006 in
Supporting Information Table 1 and in previous work.29
RESULTS
Long-Term Incidence Trends for All Races
Combined, 1975-2006
Overall cancer incidence rates for all racial/ethnic groups
combined decreased by 0.7% per year during 1999-2006
for both sexes combined, by 1.3% per year during 2000-
2006 formen, and by 0.5%per year during 1998-2006 for
women (Table 1). Trends during the most recent periods
(last joinpoint segments), along with AAPCs for the most
recent 5 years (2002-2006) and 10 years (1997-2006), are
presented for the top 15 cancers by sex. Among men, rates
decreased for cancers of the prostate, lung and bronchus
(lung), oral cavity and pharynx (oral cavity), stomach,
brain and other nervous system (brain), and for CRC. In
contrast, rates increased for cancers of the kidney and renal
pelvis (kidney), liver and intrahepatic bile duct (liver), and
esophagus and for leukemia, myeloma, and melanoma of
the skin (melanoma). Among women, incidence rates
decreased during the most recent joinpoint segments for 6
of the top 15 cancers (ie, breast, CRC, uterine corpus and
uterus not otherwise specified [uterus], ovary, cervix uteri
[cervix], and oral cavity). In contrast, rates increased for 8
of the top 15 cancers (ie, lung, thyroid, pancreas, urinary
bladder [bladder], kidney, non-Hodgkin lymphoma
[NHL],melanoma, and leukemia) in women.
On the basis of long-term trends (1975-2006), the
AAPCs for the most recent 5 years, 2002-2006, were simi-
lar to the APCs for the most recent joinpoint segment
(time period) (Table 1). When the incidence trend fluctu-
ated over time, as expected, the 10-year (1997-2006)
AAPCs differed from the most recent APCs (eg, all sites
combined for men and women; cancers of the prostate,
pancreas, and CRC in men; and cancers of the breast,
pancreas, uterus, and CRC in women). Specifically, the
Table 1. Surveillance, Epidemiology, and End Results Cancer Incidence Rate Trends With Joinpoint Analyses for
1975-2006 for the Top 15 Cancers, by Sex, for All Racesa (Continued)
Joinpoint Analyses (1975-2006)b
Trend 1 Trend 2 Trend 3 Trend 4 Trend 5 AAPCf
Sex/Cancer Site or Type Years APCe Years APCe Years APCe Years APCe Years APCe 1997-
2006
2002-
2006
Thyroid 1975-1977 6.5 1977-1980 5.3 1980-1995 2.3g 1995-2006 6.0g 6.0h 6.0h
(Delay-adjusted) 1975-1977 6.5 1977-1980 5.3 1980-1995 2.3g 1995-2006 6.3g 6.3h 6.3h
Ovaryc 1975-1985 0.1 1985-2001 0.7g 2001-2006 2.6g 1.8h 2.6h
(Delay-adjusted)c 1975-1985 0.1 1985-2001 0.7g 2001-2006 2.1g 1.5h 2.1h
Pancreas 1975-1984 1.5g 1984-1995 0.6 1995-2006 0.6g 0.6h 0.6h
(Delay-adjusted) 1975-1984 1.3g 1984-2000 0.3 2000-2006 1.7g 1.0h 1.7h
Leukemia 1975-2006 0.0 0.0 0.0
(Delay-adjusted) 1975-2006 0.3g 0.3h 0.3h
Kidney and renal pelvis 1975-2006 2.3g 2.3h 2.3h
(Delay-adjusted) 1975-2006 2.4g 2.4h 2.4h
Urinary bladder 1975-2003 0.2g 2003-2006 2.3 0.6 1.7
(Delay-adjusted) 1975-2006 0.2g 0.2h 0.2h
Cervix uteri 1975-1981 4.6g 1981-1996 1.1g 1996-2006 3.6g 3.6h 3.6h
(Delay-adjusted) 1975-1981 4.6g 1981-1996 1.1g 1996-2006 3.5g 3.5h 3.5h
Oral cavity and pharynx 1975-1980 2.6g 1980-2006 1.0g 1.0h 1.0h
(Delay-adjusted) 1975-1980 2.5 1980-2006 0.9g 0.9h 0.9h
Brain and other nervous system 1975-1987 1.6g 1987-2006 0.3 0.3 0.3
(Delay-adjusted) 1975-1987 1.6g 1987-2006 0.1 0.1 0.1
AAPC indicates average annual percent change; APC, annual percent change; NOS, not otherwise specified.
aSource: Surveillance, Epidemiology, and End results (SEER) 9 areas covering about 10% of the U.S. population (Connecticut, Hawaii, Iowa, Utah, and New
Mexico, and the metropolitan areas of San Francisco, Detroit, Atlanta, and Seattle-Puget Sound).
bJoinpoint analyses with up to 4 joinpoints are based on rates per 100,000 persons and were age-adjusted to the 2000 U.S. standard population (19 age
groups) using the Joinpoint (JP) Regression Program, version 3.3.1, April 2008, National Cancer Institute.
cAll sites excludes myelodysplastic syndromes and borderline tumors; ovary excludes borderline tumors.
dThe top 15 cancers were selected based on the sex-specific, age-adjusted incidence rates for 2002-2006 for all races combined and are listed in rank order.
eThe APC is based on rates that were age-adjusted to the 2000 U.S. standard population (19 age groups).
fThe AAPC is a weighted average of the APCs calculated by Joinpoint.
gThe APC is statistically significantly different from zero (2-sided P < .05).
hThe AAPC is statistically significantly different from zero.
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10-year AAPC (1997-2006) for prostate cancer had a
small, nonsignificant decrease that reflected a nonsignifi-
cant increase during 1995-2000 attenuated by a more
recent, significant 2.4% decline observed over the period
2000-2006. Similarly, breast cancer incidence in women
began to decline at the turn of the century after an increase
in the latter part of the 1990s (1994-1999). The 10-year
breast cancer AAPC for 1997-2006 was a smaller decline
of 1.2% per year rather than the more recent annual
decrease of 2.0% each year over the period 1999-2006.
Long-Term Mortality Trends for All Races
Combined, 1975-2006
Death rates for all cancers combined have decreased since
the early 1990s for both men and women (Table 2). The
decreases were slightly larger for men, who had declines of
1.5% per year during 1993-2001 and 2.0% per year during
2001-2006 compared with women, whose cancer death
rates declined 0.8% per year during 1994-2002 and 1.5%
per year during 2002-2006. Among the top 15 leading
causes of cancer death, mortality decreased during the most
recent period for the following sites: CRC, stomach, kid-
ney, brain, leukemia, NHL, and myeloma in both men
and women; lung, prostate, and oral cavity in men; and
breast, ovary, and bladder in women. Cancers with increas-
ing mortality during the most recent period include mela-
noma and esophageal cancer in men, pancreatic cancer in
women, and liver cancer in both men and women.
Similar to incidence trends, the AAPCs in death
rates for 2002-2006 generally were similar to the APCs
for the most recent joinpoint period. However, the use of
long-term trends often can mask changes over the shorter
term. Differences in the 5-year and 10-year AAPCs typi-
cally identify types of cancer in which the 10-year trend
may mask important recent changes. Some examples are
the accelerated rate of decline for CRC mortality for men
and for women and the recent shift toward increasing
mortality in melanoma among men.
Cancer Incidence Rates 2002-2006 and
Short-Term, Fixed-Interval Trends by Race/
Ethnicity, 1997-2006
For all cancer sites combined, for both men and
women by race/ethnicity, black men had the highest
incidence rate during 2002-2006 (Table 3). For men
in each population group, the highest incidence rates
were observed for prostate cancer, followed by lung
cancer and CRC, except among Hispanic men, whose
rate for CRC was slightly higher than for lung cancer.
Except for these 3 sites, the rank order of the top 15
cancers varied considerably among the racial/ethnic
groups. Among women, non-Hispanic women and
white women had the highest and second highest over-
all incidence rates, respectively, during 2002-2006. It
should be noted that non-Hispanic and white are not
mutually exclusive population categories. The most
common cancer site for all women, regardless of race/
ethnicity, was breast cancer. Lung cancer was the sec-
ond most common cancer, and CRC ranked third for
all races combined and for white, non-Hispanic, and
AI/AN women. However, for black, API, and Hispanic
women, CRC ranked second, and lung cancer ranked
third. For all women, cancer of the uterus ranked
fourth.
Among men, short-term trends in overall cancer
incidence rates declined significantly during 1997-2006
for each racial/ethnic group, with the least decline
observed for white and non-Hispanic men. Prostate can-
cer, the most frequently diagnosed cancer in men of all
racial/ethnic groups, declined significantly for black men
and Hispanic men. Lung cancer and CRC declined for
men in each of the racial/ethnic population groups. Uri-
nary bladder cancer declined for men in all races/ethnic-
ities combined and for men who were white, black, non-
Hispanic, and/or Hispanic. Cancer of the larynx declined
for all groups of men except AI/AN men. However, kid-
ney cancers increased among men in all of the racial/eth-
nic groups, and thyroid cancer increased among each
racial/ethnic group that had adequate numbers of cases
on which to calculate rates for estimating trends.
Women also experienced declining trends in overall
cancer incidence among each race/ethnicity except AI/AN
women. In contrast to men, the short-term AAPCs in inci-
dence rates for all cancers combined were similar among all
races/ethnicities for women and changed less. Trends in
incidence rates for breast cancer declined during 1997-
2006 except among API women. Rates of CRC and inva-
sive cancer of the cervix declined among all women except
AI/AN women. Stomach cancer declined for all women.
However, large increases in thyroid cancer were observed
during this period for women in all racial/ethnic groups.
Cancer Death Rates 2002-2006 and
Short-Term, Fixed Interval Trends by
Race/Ethnicity, 1997-2006
Death rates for all cancers combined during 2002-2006
were highest for black men and women and lowest for
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Table 2. U.S. Death Rate Trends With Joinpoint Analyses for 1975-2006 for the Top 15 Cancers, by Sex, for All Racesa
Joinpoint Analyses (1975-2006)b
Trend 1 Trend 2 Trend 3 Trend 4 Trend 5 AAPCe
Sex/cancer site or type Years APCd Years APCd Years APCd Years APCd Years APCd 1997-
2006
2002-
2006
All sites
Both sexes 1975-1990 0.5f 1990-1993 0.3 1993-2001 1.1f 2001-2006 1.6f 1.4g 1.6g
Males 1975-1979 1.0f 1979-1990 0.3f 1990-1993 0.5 1993-2001 1.5f 2001-2006 2.0f 1.8g 2.0g
Females 1975-1990 0.6f 1990-1994 0.1 1994-2002 0.8f 2002-2006 1.5f 1.1g 1.5g
Top 15 cancers for malesc
Lung and bronchus 1975-1978 2.5f 1978-1984 1.2f 1984-1990 0.4f 1990-1994 1.3f 1994-2006 2.0f 2.0g 2.0g
Prostate 1975-1987 0.9f 1987-1991 3.0f 1991-1994 0.6 1994-2006 4.1f 4.1g 4.1g
Colon and rectum 1975-1984 0.1 1984-1990 1.4f 1990-2002 2.0f 2002-2006 3.9f 2.9g 3.9g
Pancreas 1975-1986 0.9f 1986-2003 0.2f 2003-2006 1.0 0.2 0.7
Leukemia 1975-1995 0.2f 1995-2006 0.8f 0.8g 0.8g
Non-Hodgkin lymphoma 1975-1991 2.7f 1991-1997 1.7f 1997-2006 3.0f 3.0g 3.0g
Esophagus 1975-1985 0.7f 1985-1994 1.2f 1994-2006 0.4f 0.4g 0.4g
Urinary bladder 1975-1983 1.4f 1983-1987 2.7f 1987-1993 0.1 1993-2003 0.6f 2003-2006 0.7 0.2 0.4
Liver and intrahepatic
bile duct
1975-1979 0.3 1979-1987 2.3f 1987-1996 3.9f 1996-1999 0.5 1999-2006 2.4f 2.0g 2.4g
Kidney and renal pelvis 1975-1991 1.1f 1991-2002 0.1 2002-2006 1.5f 0.7g 1.5g
Stomach 1975-1994 2.1f 1994-2006 3.7f 3.7g 3.7g
Brain and other
nervous system
1975-1977 4.4 1977-1982 0.4 1982-1991 1.3f 1991-2006 1.0f 1.0g 1.0g
Myeloma 1975-1994 1.5f 1994-2006 1.1f 1.1g 1.1g
Oral cavity and pharynx 1975-1980 0.9 1980-2006 2.2f 2.2g 2.2g
Melanoma of the skin 1975-1987 2.4f 1987-1998 0.7f 1998-2002 1.5 2002-2006 2.0f 0.3 2.0g
Top 15 cancers for femalesc
Lung and bronchus 1975-1982 6.0f 1982-1990 4.2f 1990-1995 1.7f 1995-2003 0.3f 2003-2006 0.9 0.1 0.6
Breast 1975-1990 0.4f 1990-1995 1.8f 1995-1998 3.3f 1998-2006 1.9f 2.0g 1.9g
Colon and rectum 1975-1984 1.0f 1984-2001 1.8f 2001-2006 3.4f 2.7g 3.4g
Pancreas 1975-1984 0.8f 1984-2006 0.1f 0.1g 0.1g
Ovary 1975-1982 1.2f 1982-1992 0.3f 1992-1998 1.2f 1998-2002 0.7 2002-2006 1.4f 0.4 1.4g
Non-Hodgkin lymphoma 1975-1997 2.1f 1997-2006 3.7f 3.7g 3.7g
Leukemia 1975-1980 0.7 1980-2000 0.4f 2000-2006 1.6f 1.2g 1.6g
Corpus and uterus, NOS 1975-1992 1.5f 1992-2006 0.0 0.0 0.0
Brain and other
nervous system
1975-1992 1.0f 1992-2006 1.1f 1.1g 1.1g
Liver and intrahepatic
bile duct
1975-1978 1.5 1978-1988 1.4f 1988-1995 4.0f 1995-2000 0.2 2000-2006 1.8f 1.3g 1.8g
Myeloma 1975-1993 1.5f 1993-2001 0.4 2001-2006 2.4f 1.5g 2.4g
Stomach 1975-1987 2.8f 1987-1990 0.3 1990-2006 2.7f 2.7g 2.7g
Kidney and renal pelvis 1975-1992 1.3f 1992-2006 0.6f 0.6g 0.6g
Cervix uteri 1975-1982 4.4f 1982-1996 1.6f 1996-2003 3.8f 2003-2006 0.7 2.8g 1.5
Urinary bladder 1975-1986 1.7f 1986-2006 0.4f 0.4g 0.4g
AAPC indicates average annual percent change; APC, annual percent change; NOS, not otherwise specified.
aSource: National Center for Health Statistics public-use data file for the total United States.
bJoinpoint analyses with up to 4 joinpoints are based on rates per 100,000 persons and were age-adjusted to the 2000 U.S. standard population (19 age
groups). Joinpoint (JP) Regression Program, version 3.2.0, January 2008, National Cancer Institute.
cThe top 15 cancers were selected based on the sex-specific, age-adjusted death rates for 2001-2005 for all races combined and listed in rank order.
dThe APC is based on rates that were age-adjusted to the 2000 U.S. standard population (19 age groups).
eThe AAPC is a weighted average of the APCs calculated by Joinpoint.
fThe APC is statistically significantly different from zero (2-sided P < .05).
gThe AAPC is statistically significantly different from zero.
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API men and women (Table 4). Lung and prostate can-
cers and CRC were among the 3 leading causes of cancer
death for men in each major racial/ethnic group except for
API men, for whom liver cancer ranked second. Among
most women, the leading causes of cancer death were lung
and breast cancers, CRC, and pancreatic cancer. How-
ever, among Hispanic women, breast cancer was the lead-
ing cause of cancer death. Specific rankings for the other
15 types of cancer also varied within the racial/ethnic
groups by sex.
During 1997-2006, short-term trends in death rates
for all cancers combined decreased for all racial/ethnic
groups and for both men and women, except for AI/AN
women. Similarly, lung cancer mortality trends decreased
for all racial/ethnic groups of men as did trends for pros-
tate cancer and CRC except among AI/AN men. Liver
cancer death rates increased for all men except API men,
whose rates decreased, and except AI/AN men. Short-
term trends for breast cancer death rates decreased in
white, black, Hispanic, and non-Hispanic women; and
CRC death rates decreased for all women except those
who were Hispanic or AI/AN. Among women, short-
term lung cancer death rate trends decreased for white,
API, and Hispanic women but increased for AI/AN
women. Short-term mortality trends for most other types
of cancer had considerable variability among racial/ethnic
population groups of women. Trends in death rates of
pancreatic cancer increased for white men and women but
decreased for black men and women.
CRC Incidence (by Age, Subsite, and Stage),
Mortality, and Stage-Specific Survival Trends
Long-term incidence trends for CRC (based on SEER 9)
have been fairly consistent in men and women (Table 1),
with increasing incidence (for men) during 1975-1985,
marked declines during 1985-1995 for men and women
followed by a short nonsignificant increase (1995-1998),
and marked declines during 1998-2006. CRC death rates
(Table 2) have declined since 1984 in both men and
women, with an accelerated rate of decline since 2002 (for
men) and 2001 (for women). During the most recent dec-
ade (1997-2006, based on pooled data) (see Table 3),
short-term trends in CRC incidence declined for all
racial/ethnic groups, for men, and for women (except AI/
ANs); the fastest annual rate of decline occurred among
men and women aged 65 years (a data table is available
at www.seer.gov/report_to_nation/1975_2006 [Support-
ing Information Table 2]) compared with younger indi-
viduals. In contrast, short-term incidence trends increased
annually for individuals aged<50 years within most pop-
ulation groups with few exceptions. Incidence rates by
major anatomic subsites (proximal colon, distal colon,
rectum) varied considerably by race, sex, and age (see the
data table at www.seer.cancer.gov/report_to_nation/
1975_2006 [Supporting Information Table 2]). Inci-
dence rates for all ages combined for distal colon and rec-
tal cancers decreased among men and women in every
racial/ethnic group except for distal colon cancer among
AI/AN men and women. In contrast, among individuals
aged <50 years, incidence rates for distal colon and rectal
cancers increased in men and women of all race/ethnicities
combined, in white men and women, and in black men.
Rates for proximal colon cancer decreased in men and
women of all race/ethnicities combined but decreased by
subgroup only for white men and women, API men, and
Hispanic women.
Trends in stage-specific incidence rates ([Fig. 2A]
and a data table [available at www.seer.cancer.gov/
report_to_nation/1975-2006] [Supporting Information
Table 3]) for the SEER 9 data revealed annual increases in
the incidence of localized cancer from 1975 to 1987 (APC
¼ 1.8%), declines from 1987 to 1995 (APC ¼ -2.1%),
and nonsignificant increases from 1995 to 1999, followed
by decreases between 1999 and 2006 (APC ¼ -2.2%).
Incidence rates of regional cancer increased between 1975
and 1985 (APC¼ 1.8%), decreased markedly but not sig-
nificantly from 1985 to 1988 (APC ¼ -5.0%), and
decreased significantly thereafter by 0.8% per year from
1988 to 2001 and by 5.0% per year between 2001 and
2006. Incidence rates of distant cancer decreased steadily
between 1975 and 2006 by 1.3% per year. Incidence rates
of unstaged cancer decreased by 2.8% per year between
1975 and 1997 and by 5.7% per year during the 10-year
interval from 1997 to 2006. CRC 5-year relative survival
has improved throughout the period 1975-2001 (Fig. 2B)
for all patients in each stage category. Relative survival rate
at 5 years for the most recent diagnosis years are 90% for
localized disease, 70% for regional disease, and 12% for
distant disease.
Past and Future Trends in CRC Incidence and
Death Rates: Impact of Risk Factors,
Screening, and Treatment
Figure 3 illustrates the age-standardized CRC incidence
rates by calendar year 1975-2000 for SEER 9 registries
(adjusted to represent first primary CRCs) and for the
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MISCAN-Colon model estimated rates. There are 2 lines
with estimated rates for MISCAN. One line represents
the model-predicted CRC incidence rates based on
observed trends in risk factor prevalence and screening
uptake. The other line represents the model-predicted
rates when only changes in risk factors would have
occurred and no screening had taken place. The overall
observed decline in CRC incidence was 22% for 1975-
2000. The MISCAN model-predicted decline without
screening was 11%, indicating that changes in risk factors
accounted for 50% of the overall decline in incidence rates
during 1975-2000. Screening affected the CRC incidence
rates adversely in the short term but then accounted for
50% of the CRC incidence decline for the period.
Figure 4 illustrates the age-standardized observed
and MISCAN model-predicted CRC US death rates by
calendar year from 1975-2000. There are 3 lines with esti-
mateddeath rates.One line represents themodel-predicted
CRC mortality based on observed trends in risk factor
prevalence, screening uptake, and treatment use. Another
line represents the model-predicted death rates when only
risk factors and screening changed over time, and the last
line represents the model-predicted mortality for changes
in risk factors only. The overall observed decline in CRC
mortality was 26% for 1975-2000. The model predicted
that, with only changes in risk factors, CRC mortality
would decrease by 9%, explaining 35% of the observed
mortality decline. Screening decreased mortality by
another 14%, explaining 53% of the mortality reduction,
whereas treatment added another 3% decline, explaining
the final 12%of the observed decline inCRCmortality.
The microsimulation modeling also projected future
CRC mortality based on differing intensities of cancer
control, including no change (pre-2000, frozen), contin-
ued trends, and optimistic trends in the prevalence of
interventions (Fig. 5).29 Without changes in risk factors,
Figure 2. (A) Trends in stage-specific age-standardized colorectal cancer (CRC) incidence rates by year of diagnosis (1975–
2006) for all races, both sexes. Joinpoint regression with up to 4 joinpoints are calculated using Version 3.3.1 (April 2008)
from the National Cancer Institute. (B) Trends in CRC 5-year relative survival by stage at diagnosis and year of diagnosis
(1975-2001) for all races, both sexes. Data are from the Surveillance, Epidemiology, and End Results (SEER) 9 areas which
cover about 10% of the U.S. population. Stage analyses were based on Extent of Disease (EOD) and Collaborative Stage
(CS) Data Collection System. Incidence rates are age-adjusted to the 2000 US Std Population (19 age groups). Relative
survival was calculated with the SEER*Stat software (http://www.seer.cancer.gov/seerstat) version 6.5.2: NCI; 2009.
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screening, and treatment (frozen as of 2000), the decline
in CRC mortality may only be 17%. However, the MIS-
CAN-Colon model predicts a 36% overall decline in
CRC mortality from 2000 to 2020 if current trends in
risk factors, screening, and treatment continue. If we can
accelerate the projected trends, then an overall mortality
reduction of 50% by 2020 is possible. Figure 6 illustrates
the contribution of the 3 types of interventions to this op-
timistic reduction in mortality. Risk factor modifications,
although they require the longest time to produce an
impact, will have a sizable effect by 2020. Increases in the
proportion of adults screened and in the use of endoscopic
CRC screening will provide the largest reduction in future
death rates with application of current state-of-screening
technologies, risk factor modification, and use of current
treatment practices.
DISCUSSION
This Annual Report to the Nation documents continued
declines in incidence and mortality rates from all cancers
combined among bothmen and women. However, cancer
incidence and mortality vary by specific types of cancer
and by sex and racial/ethnic group. Decreases in incidence
and death rates are greater for men than for women
(Tables 1 and 2), but overall rates continue to be much
higher for men than for women (Tables 3 and 4). Inci-
dence rates for the 3 leading causes of cancer for men
(prostate and lung cancer and CRC) all declined along
with 3 more of the top 15 cancers (ie, oral cavity, stomach,
and brain) (Table 1), as in past years. However, incidence
rates increased for kidney, liver, and esophageal cancers
and for leukemia, myeloma, and melanoma; rates did not
change for bladder or pancreatic cancers or for NHL. For
the top 3 cancers among women, breast cancer and CRC
incidence rates declined, but lung cancer incidence rates
increased. Of the remaining 15 leading cancers for
women, incidence rates also declined for cancers of the
uterus, ovary, cervix, and oral cavity but increased for can-
cers of the lung, thyroid, pancreas, bladder, and kidney
and for NHL, melanoma, and leukemia.
The continued decline in death rates (Table 2)
from all cancers combined for men and women reflects
Figure 3. Partition of past trends in colorectal cancer incidence (1975–2000). The age-adjusted rates are given by year of colo-
rectal cancer (CRC) diagnoses. The black line is the observed Surveillance, Epidemiology, and End Results (SEER) CRC incidence
rates based on first primary CRC. The red line is the microsimulation screening analysis (MISCAN) model estimate of the CRC
incidence rate in the time period 1975–2000 based on the natural history of the CRC overlaid by the changes in the prevalence
of risk factors and the uptake of CRC screening during this time period. The green line is the MISCAN model estimate of CRC
incidence in this time period if only risk factor changes had occurred without screening increases. The shaded green area repre-
sents the impact of risk factor changes on incidence in the time period 1965–2000 (see text). The orange area represents the
additional impact of increases in screening over and above the changes due to risk factors alone for this period. Rates are based
on the first primary CRC and include the primary sites of C18.0 C18.2-C18.9, C19.9, C20.9 and the ICD-03 histologies of: 8000–
8001, 8010, 8020, 8140, 8210–8211, 8220–8221, 8260–8263, 8480–8481, 8490. Rates do not include cases that are from a report-
ing source of death certificate only or autopsy only.
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the impact of increased screening, reduction of risk fac-
tors, and improved treatment. Risk factors generally
affect disease development over the long term rather
than the short term, so education and prevention efforts
begun decades ago may be reflected in the current
decreased cancer mortality. Decreases in cancer mortal-
ity rates for men were greater than for women; but, as
with incidence rates, cancer mortality rates generally are
much higher for men than for women. Of the 15 most
frequently occurring cancers among men in the most
recent time period (Table 2), decreases occurred in
death rates for cancers of the stomach, kidney, brain,
lung, prostate, and oral cavity and for CRC, leukemia,
NHL, and myeloma. Death rates among men increased
for melanoma and for liver and esophageal cancers.
Among women in the most recent time period (Table
2), mortality rates decreased for CRC and for cancers of
the stomach, kidney, brain, breast, ovary, and bladder
as well as for leukemia, NHL, and myeloma; however,
death rates for women increased for pancreatic and liver
cancers. Liver cancer was the only cancer for which
death rates increased for both men and women, suggest-
ing a need to identify and implement interventions that
can reduce mortality from this cancer.
Of the leading cancers, prostate cancer is of special
note, because it is the most frequently diagnosed cancer
and is second leading cause of cancer death among men.
Incidence for prostate cancer has fluctuated through the
years, increasing during 1975-1992, decreasing during
1992-1995, increasing (nonsignificantly) during 1995-
2000, and decreasing again during 2000-2006 (Table 1).
The few randomized trials on prostate cancer screening
produced conflicting results with various methodolo-
gies.56,57 Consequently, comparative microsimulation
modeling is being used to better understand the progres-
sion of the disease, the impact of screening on mortality,
and cost implications of expanded prostate screening.58-60
A CISNET prostate cancer project is using available data
to model the impact of screening on prostate cancer inci-
dence and mortality. Screening for breast cancer, the most
Figure 4. Partition of past trends in colorectal cancer mortality (1975–2000). The age-adjusted rates are given by year of colo-
rectal cancer (CRC) diagnoses. The black line is the observed US CRC age-adjusted death rate for 1975–2005. The purple line is
the microsimulation screening analysis (MISCAN) model estimate of CRC in the time period 1975–2000 based on the natural his-
tory of CRC overlaid by the changes in the prevalence of risk factors, the uptake of CRC screening, and dissemination of treat-
ment during this time period. The red line is the MISCAN model estimate of CRC in the time period 1975–2000 based on the
natural history of CRC overlaid by the changes in the prevalence of risk factors and the uptake of CRC screening during this time
period minus treatment. The green line is the MISCAN model estimate of CRC mortality in this time period if only risk factor
changes had occurred and not increases in screening and treatment as well. The shaded green area represents the impact of risk
factor changes on mortality in the time period 1965–2000 (see text). The orange area represents the additional contribution to
the decline in mortality of screening increases over and above that due to changes in risk factors in this period. The purple area
represents the additional contribution of treatment over and above that of risk factor and screening effects on the mortality
decline. Source: CDC National Center for Health Statistics, National Vital Statistics System. Heron M, Hoyert DL, Murphy SL, Xu J,
Kochanek KD, Tejada-Vera B. Deaths: Final data for 2006. National Vital Statistics Reports, April 17, 2009, 57(14).
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frequently diagnosed cancer and the second leading cause
of cancer death among women, already is recommended
for women.61 Breast cancer incidence also has fluctuated
with increases and decreases over time (Table 1) but
declined 1.5% per year during 2002-2006 (Table 3).
Among racial and ethnic groups, the highest cancer
death rates occurred among black men and women, and
the lowest rates occurred among API men and women
(Table 4). However, pancreatic cancer death rates, the
fourth most common cause of cancer death in the United
States, increased among white individuals but decreased
among black individuals. The 3 leading causes of cancer
deaths by racial and ethnic group for men were lung and
prostate cancers and CRC. This ranking varied only
for API men, for whom lung and liver cancers and
CRC were the leading cancers. Among women by racial/
ethnic group, the leading causes of cancer deaths were
lung and breast cancers and CRC, except for Hispanic
women, for whom breast cancer ranked first. Mortality
for the top 3 cancers declined for men among all racial
and ethnic groups, and breast and CRC declined for
women. CRC death rates decreased for women in all
racial and ethnic groups except AI/AN and Hispanic
women. The differences and fluctuations in death rates
for specific cancers for different racial and ethnic groups
and for men and women suggest differences in risk behav-
iors, socioeconomic status, and access to and use of screen-
ing and treatment.62-64
This report highlights CRC, currently the third
most frequently diagnosed cancer and the second leading
cause of cancer deaths in the United States for men and
women combined. Globally, CRC incidence in economi-
cally transitioning countries continues to rise because of
increased exposure to risk factors; however, in economi-
cally developed countries, rates have stabilized or are
declining.65,66 In the United States, an estimated 147,000
individuals will be diagnosed with CRC in 2009, and
approximately 50,000 will die of the disease.62,67
Table 1 shows that, since 1985, CRC incidence rates
have declined for both men and women except during
1995-1998. The age-adjusted CRC incidence rates for
1997-2006 declined among both men and women aged
Figure 5. Projections of colorectal cancer mortality with differing intensities of cancer control interventions (2000–2020). The
age-adjusted colorectal cancer (CRC) death rates are presented by year of death. The black line is the age-adjusted US mortality
rate (1975–2006). The gray line is the microsimulation screening analysis (MISCAN) modeling of the age-adjusted mortality 1975
to 2000 based on the past trends in risk factors, screening, and treatment (the purple line of Figure 3). There are 3 levels of can-
cer control interventions of risk factors, screening, and treatment. The blue line represents the projected CRC mortality if the
upstream factors for risk factors, screening, and treatment remain at the same level as for 2000. This scenario is called frozen (at
2000). The orange line represents the projected CRC mortality if the upstream factors continued according to the trend of these
factors in 1995–2000. This scenario is called continuing trends. The red line represents the projected CRC mortality if the
upstream factors for risk factors, screening, and treatment improve over and above that of continued trends to an optimistic level
for each factor. This scenario is called optimistic trends. The blue area represents the improvement in CRC mortality based on the
pre-2000 trends in upstream factors. The yellow area represents the additional impact of post-2000 continued trends in
upstream factors. The red area represents the additional impact of post-2000 optimistic trends in upstream factors. Source: CDC
National Center for Health Statistics, National Vital Statistics System. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-
Vera B. Deaths: Final data for 2006. National Vital Statistics Reports, April 17, 2009, 57(14).
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50 years but increased among those aged <50 years (a
data table is available at www.seer.cancer.gov/report_to_
nation/1975_2006 [Supporting Information Table 2]).
Although men generally had slightly greater rates of
decline than women, incidence rates for men remained
considerably higher than for women. Although >90% of
newly diagnosed cases of CRC occurred among individu-
als aged 50 years (a data table is available at www.seer.
cancer.gov/report_to_nation/1975_2006 [Supporting In-
formation Table 2]), increasing incidence among younger
men and women is of concern, suggesting future increases
in CRC as these populations age that could be exacerbated
by increasing prevalence of obesity and unfavorable die-
tary changes.68 Individuals aged <50 years also are more
likely to be diagnosed with later stage and less differenti-
ated CRC69 than older individuals, likely reflecting the
benefits of screening in older populations. Age-adjusted
incidence rates for individuals aged <50 years were high-
est among black individuals and lowest for individuals of
Hispanic ethnicity but are increasing most rapidly for the
AI/AN population. For older adults, incidence rates were
highest among black individuals and were disproportion-
ately high among those ages 50-64 years. Individuals aged
65 years are more at risk for CRC, have higher incidence
(with rapid annual declines in trends), and have higher
rates of CRC test use compared with individuals aged
<65 years.70,71 The burden of CRC mortality is concen-
trated in older individuals, with 6% of deaths in 2006
among individuals aged<50 years, 20% among individu-
als ages 50-64 years, and 74% among individuals aged
65 years.19,22
Screening appears to have had considerable impact
on reducing CRC incidence and mortality.36 CRC
screening was introduced in the 1970s and 1980s, when
researchers demonstrated the feasibility of testing for
occult blood in stool and initiated randomized clinical tri-
als. In 1985, the diagnosis of colon cancer in President
Ronald Reagan increased public awareness of CRC, as
demonstrated by a documented increase in the use of tests
for early detection of CRC among Medicare recipients
and an increase in CRC incidence, particularly for early
stage disease.72 During 1987-1998, gradual increases in
screening for CRC occurred.70 Results of randomized
clinical trials of FOBT, which demonstrated reductions in
Figure 6. Contributions of risk factors, screening, and treatment to optimistic projections of colorectal cancer (CRC) mortality
(2000–2020). The black line is the age-adjusted US death rate (1975–2006) by age at death. The gray line is the microsimulation
screening analysis (MISCAN) modeling of the age-adjusted mortality 1975 to 2000 based on the past trends in risk factors,
screening, and treatment (the purple line of Figure 3). The heavy blue line is the MISCAN model projection based on pre-2000
upstream factors (frozen scenario) (blue line of Figure 5). The next lines represent the individual components of the opportunistic
trends models. The green line represents the projected age-adjusted CRC mortality if only optimistic treatment interventions are
implemented. The orange line represents the age-adjusted CRC death rate if only optimistic risk factor interventions were imple-
mented. The purple line represents the CRC mortality rate if only optimistic screening was implemented. The heavy red line repre-
sents the CRC death rate for the combined effect of implementing risk factor, screening, and treatment interventions (same line
as red line in Figure 5). Source: CDC National Center for Health Statistics, National Vital Statistics System. Heron M, Hoyert DL,
Murphy SL, Xu J, Kochanek KD, Tejada-Vera B. Deaths: Final data for 2006. National Vital Statistics Reports, April 17, 2009,
57(14).
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both CRC mortality and incidence, provided strong evi-
dence for recommending this test73,74; FOBT continues
to be a recommended screening option if performed
annually.75-77 Colonoscopy was introduced as a method
for screening the entire colon in the 1990s and has been
recommended as a screening test for average-risk individ-
uals aged 50 years since 1997.77 Recent guidelines dis-
tinguish between screening tests that primarily detect
cancer and those that are more likely to detect both cancer
and adenomatous polyps.75 Rates of CRC screening have
continued to increase from 2000 to 2008, with a marked
shift from sigmoidoscopy to colonoscopy for endoscopic
screening and a declining use of FOBT (C. Klabunde,
unpublished data).70,71,78-80
Research is ongoing regarding the most effective
screening methods, individuals most at risk, and optimal
surveillance intervals. Simulation models and meta-analy-
ses of published literature have provided insight and
potential cost-effective guidelines for policy and health-
care. Although the organizations involved in CRC preven-
tion and control have differing recommendations for
specific aspects of CRC screening, there is consensus that
adults should begin screening at age 50 years, preferably
by methods likely to detect cancer and adenomas before
they develop into cancer.36 Recent data suggest that
approximately 50% of individuals aged 50 years have
been screened according to recommended time intervals
(C. Klabunde, unpublished data), with the highest rates
of CRC screening (60% in 2008) among individuals
aged65 years. The proportion screened remains<70%,
the rate used by MISCAN-Colon when projecting CRC
mortality reductions using optimistic changes in upstream
factors; however, rates of colonoscopy screening have
increased, whereas rates of FOBT and sigmoidoscopy
have declined70 (C. Klabunde, unpublished data).
A recent assessment of screening methods indicated
that, with high rates of adherence for each method, similar
gains in life-years resulted from several screening methods:
colonoscopy every 10 years, annual high-sensitivity
FOBT, and flexible sigmoidoscopy every 5 years with
Hemoccult SENSA (Beckman Coulter, Inc., Miami, Fla)
every 2-3 years.36 Also, it has been demonstrated that
computed tomographic colonography is potentially as
effective as colonoscopy if conducted every 5 years with
follow-up for those with polyps 6 mm.35 Although
colonoscopy screening appears to have gained acceptance
among healthcare professionals and patients, resources for
colonoscopy may limit its use as a primary screening
modality.78,79 For colonoscopy to be beneficial, down-
stream resources need to be available to patients who
screen positive, including follow-up colonoscopy after
positive results of other screening tests, diagnostic colono-
scopy for symptomatic patients, and surveillance colono-
scopy after diagnosis of an adenoma or adenocarcinoma.
Although risks for adverse events from colonoscopy are
low, they increase with age in part because of comorbid-
ities.81 Some guidelines suggest discontinuing screening
of individuals aged >75 years,77 but only approximately
33% of surveyed physicians reported that they stop rec-
ommending screening when healthy patients reach a cer-
tain age, most commonly at age 80 years.80
A family history of CRC and a personal history of
CRC, colorectal polyps, or chronic inflammatory bowel
disease are major risk factors for CRC.82,83 The risk for
CRC is approximately twice that of an average individual
for those who have a first-degree relative (parent, sibling,
or child) who has had CRC; the risk is even greater if the
relative was diagnosed at a young age or if more than 1
first-degree relative has had CRC.84,85 Individuals with
these risk factors may be advised to begin screening before
age 50 years, when screening is recommended for average
risk individuals. Individuals with certain inherited genetic
alterations, such as familial adenomatous polyposis or
hereditary nonpolyposis colorectal cancer (also known
as Lynch syndrome),86 are at even higher risk of develop-
ing CRC and should be identified and carefully
monitored.87
Other major risk factors for CRC that are poten-
tially modifiable include physical inactivity, being over-
weight and obese, and a diet high in red and processed
meats.88-101 Modification of these risk factors requires be-
havioral changes that are difficult but important to
achieve and impact many health outcomes in addition to
CRC. Decreasing the prevalence of these risk factors can
be protective against CRC, although changes are expected
to result in long-term, not short-term, gains.102 Changes
in community factors and health policy can be important
tools for changing individual behaviors. The need for
national policy and programs that engage communities in
working toward improved nutrition and physical activity,
smoking cessation, and decreased alcohol use has been
widely recognized. The CDC has proposed a program of
16 community-level initiatives to promote healthy life-
styles through increasing availability of affordable, healthy
foods and beverages; encouraging physical activity among
youth and adults; and promoting environments that sup-
port physical activity. The program fosters partnerships
and collaborations to implement the strategies and
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evaluate outcomes to assess progress toward a healthier
nation.103
Continued declines in tobacco use in the United
States likely will contribute toward declining trends in
CRC incidence. Although neither the 2004 monograph
on smoking from the International Agency for Research
on Cancer104 nor the 2004 Surgeon General’s report on
smoking105 classified CRC as a smoking-related cancer,
consistent evidence demonstrates that smoking increases
the development of adenomatous polyps, particularly
more aggressive adenomas.106 Also, increasingly strong
and consistent evidence indicates that smoking is associ-
ated with CRC, especially with rectal cancer.107-109 Fur-
thermore, although more research is required to assess the
benefits and risks of chemoprevention, use of anti-inflam-
matory drugs, dietary supplements (eg, calcium),
and multivitamins could be protective against this
cancer.110-114
CRC incidence varies by state and county, presum-
ably because of differences in screening resources and
access to care if residence is in an underserved community.
One study associates high CRC incidence rates for white
and black individuals with residence in counties that had
high uninsured or poverty rates, fewer primary physicians,
and large proportions of rural or underserved areas.115
However, another US study demonstrated that white
individuals living in high-income counties had higher
CRC incidence for proximal cancer than those living in
middle-poverty or high-poverty counties, suggesting that
lifestyle factors such as diet, which is influenced by eco-
nomic status, play a prominent role in geographic varia-
tions in CRC incidence.116
The microsimulation models created by CISNET
estimate the extent to which CRC incidence and mortality
can be reduced through interventions and treatment and
can predict the effects of various scenarios on CRC out-
comes. This research indicates that, if 1995-2000 trends
for risk factor prevalence, screening, and treatment con-
tinue, then death rates from CRC could be reduced by
36% by 2020. However, adverse trends in some risk fac-
tors can neutralize gains in others, so gains must be
assessed over a long period of time for observed impact.102
If intervention efforts are successful and increase beyond
those of 1995-2000, then deaths from CRC could be sub-
stantially reduced. CISNET modeling demonstrates what
would be required to reduce the impact of CRC in the
United States. An estimated $8.4 billion is spent annually
on CRC treatment,117 which will increase as CRC preva-
lence increases to an expected 1.5 million individuals by
2020,118 with most healthcare costs devoted to the initial
year after diagnosis.119
Limitations
Cancer surveillance in the United States now covers the
majority of the population for monitoring incidence and
the entire population for monitoring mortality. However,
certain limitations in data sources, data collection, and
analyses may have influenced the findings of this report.
First, state and national population estimates that were
provided by the Census Bureau from 2000 forward and
were used initially with statistical reporting last year were
developed by using improved and more accurate method-
ologies, which had noticeable effects on age-specific rates
for some counties and states. The net impact of those
changes for 2006 was a downward shift in the current
postcensus estimates (caused primarily by net interna-
tional migration estimation) compared with postcensus
estimates that were used in the previous report. National
incidence rates and death rates were not affected, but
some state-level rates were. The NCI also developed mod-
ifications to these census estimates in an attempt to
account for changes in 2005 county-level populations
because of displacement of individuals after hurricanes
Katrina and Rita in the most affected counties of Louisi-
ana, Mississippi, Alabama, and Texas.
Second, we used 3 different statistical methods for 2
geographic sets of aggregate data to describe cancer trends:
Initially, a single linear regression model was used to
describe short-term trends (1997-2006) by race and eth-
nicity for geographic areas that covered 71% of the United
States; next, a joinpoint model was used to describe long-
term trends (1975-2006) for all races and ethnicities com-
bined in a subset of these geographic areas that covered
approximately 10% of the US population; finally, the
AAPC, a new summary measure of a trend over a prespe-
cified fixed interval based on an underlying joinpoint
model, was introduced in this report. The joinpoint
model is preferable to single linear regression when suffi-
cient numbers of years are available for analysis, because it
enables the identification of recent changes in magnitude
and direction of trends, although the trends may be unsta-
ble when analyses are based on rates with large variance
and when statistical power is low for detecting joinpoint
segments. The AAPC can be estimated even if the join-
point model indicates changes in trends during those
years, because this measure is the geometric weighted aver-
age of the joinpoint segments over the interval. Enough
years of data are now available to use joinpoint analysis for
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trends by race and ethnicity, and we have used the AAPC
based on up to 2 line segments over the 10-year fixed pe-
riod to report multiple sites and racial and ethnic groups.
Methods have yet to be adapted for delayed reporting of
aggregated data, except for incidence from the 9 oldest
SEER registries. Delayed reporting may affect the most
recent joinpoint segment for the national data.
Third, the Veterans Health Administration (VA)
hospitals traditionally have been a critical source of data
for cancers diagnosed among veterans who are eligible to
receive care from these facilities, representing approxi-
mately 3% to 8% of cancer diagnoses among men. A
2007 policy change regarding the transfer of VA cancer
data to state central cancer registries has resulted in incom-
plete reporting of VA hospital cases in some registries.
This change affected reporting beginning with the third
quarter 2004 diagnosis year through the end of the 2006
diagnosis year (available at: http://seer.cancer.gov/
csr/1975_2006/results_merged/sect_33_VA_adjust-
ment.pdf accessed on August 21, 2009). Conse-
quently, cancer incidence rates among men for 2005
and 2006 in the SEER 17 registries, which cover
>25% of the US population, were underestimated
by 1% to 2% for all cancers combined. The level of
under reporting varied from 0.5% to 4% according
to cancer site, race, and age group.13,120 By using
similar methods, cancer incidence rates for 2006
among men in the 31 NPCR registries that provided
data to the CDC were underestimated between 0.3%
to 11.2% (C. Eheman, unpublished data). The
amount of underestimation based on data from other
geographic areas may vary by local VA facility
reporting patterns and the VA’s contribution to the
total number of cancers. In late 2008, data-transfer
agreements were being established between many VA
facilities and states with central registries. Over time,
as cancer registries receive these missing VA cases,
national cancer incidence estimates will be more
complete.
Fourth, assessment of stage-specific CRC incidence
trends was limited by a change in methods used to collect
information on stage beginning with 2004 diagnoses. The
improvements in the use of the Coding System for Col-
laborative Stage (CS) (available at: http://www.cancersta-
ging.org/cstage/index.html accessed on September 30,
2009) created an artifact in the trend between the 2003
and the 2004 diagnosis years for most state registries
funded by the CDC (data not shown). The SEER 9 data-
base was used to estimate stage-specific CRC incidence
trends, because the SEER Program has used Extent of
Disease since 1988 and CS since 2004 for comparability
of information on stage across changes in coding rules.
Fifth, the national estimates of prevalent use of
CRC screening and early detection tests were based on
trend data from respondents aged 50 years who partici-
pated in the NHIS. These estimates, although they were
based on smaller sample sizes with substantially higher
response rates than data from the Behavioral Risk Factor
Surveillance Survey (BRFSS),121 tend to be slightly lower
than BRFSS estimates.71 Differences in estimated preva-
lence may be caused by differences in the mode of admin-
istration and response rates from the telephone-based
BRFSS compared with the interviewer-administered
NHIS. NHIS in-person surveys also provide access to
households without telephones and cell-phone-only
households, which cannot be reached by means of ran-
dom-digit-dial surveys, such as that used by the BRFSS.
These factors point to the importance of mixed-mode sur-
vey methodology and alternative frames for mitigating the
increase in telephone survey nonresponse, which erodes
coverage of random-digit-dial telephone sampling
frames.122
Sixth, as noted routinely in the annual reports,1-11
the broad racial and ethnic groups categorized for our
analyses may mask variations in the cancer burden by
country of origin, eg, Chinese and Vietnamese in the API
group123 and Cubans and Mexicans in the Hispanic
group,8,124 or by other unique characteristics of high-risk
populations.125-128 Also, cancer rates for populations may
be limited by difficulties in ascertaining race and ethnicity
information from medical records, death certificates, and
census reports.129
Finally, the MISCAN-Colon model inputs were
constrained to those previously used in the published
results (available at: http://cisnet.cancer.gov/projections/
colorectal accessed on September 30, 2009).29 The cur-
rent report did not re-examine assumptions concerning
risk factors, screening, or treatment interventions, because
the perspective was on their relative importance. Addi-
tional studies by the MISCAN-Colon modeling group
will examine trends in screening modalities as well as
other factors that were not incorporated into earlier mod-
els. The observed SEER 9 incidence data presented with
the MISCAN-Colon model results were adjusted to
reflect first primary incidence rates rather than any pri-
mary, with adjustments for apparent over reporting of
first primary CRC tumors during the early years of the
registry using information from the most recent
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diagnostic years reported in the cancer registries. Minor
restrictions in histologic subsites and the exclusion of
death-only cases for CRC as reported by SEER were made
for the MISCAN-Colon model with little impact on
model predictions.
Future Directions
The observed decreases in incidence and death rates from
all cancers combined amongmen and women overall and in
nearly all racial and ethnic groups are highly encouraging.
This progress must be viewed as part of a long-term strategy
for substantial reductions in cancer incidence and mortality
through improved risk factors, increased early detection,
and better treatment. However, progress has beenmore lim-
ited for some types of cancer for which breakthroughs in
prevention, early detection, and treatment remain elusive.
Cancer is multifaceted, and many approaches and aspects of
this disease affect outcomes for cancer patients. This section
summarizes key considerations for future directions in can-
cer research and interventions.
Microsimulation modeling provides evidence-based
support for decisions regarding effective policy and
resource allocation for cancer interventions. The models
use available data to project outcomes of possible scenar-
ios concerning risk factors, screening, and treatment and
are important for decision making when observed data are
unavailable or inadequate. For example, CISNET is
working on models for prostate cancer to better under-
stand the progression of this leading cause of cancer inci-
dence among men and to assess the benefits of increased
prostate screening.56,57
Cancer surveillance systems, which capture preva-
lence of cancers by age, sex, geographic locations, and
other variables, also contribute to informed decision mak-
ing by enabling an understanding of trends in various
aspects of cancer, including diagnosis and treatment.
Foundational for cancer prevention and control efforts,
the enhancement of cancer registries and surveillance sys-
tems can enable a more comprehensive understanding
and tracking of cancer and public health and medical
interventions.
Many cancers have modifiable risk factors, although
risk factor reduction usually results in long-term, not
short-term, improvements in cancer incidence. Thus, the
impact of changing prevalence of CRC risk factors must
be assessed over a long time to observe impact.102 For
example, tobacco prevention efforts over the past decades
likely are reflected in recent reductions in lung cancer inci-
dence. Also, research demonstrates that states with com-
prehensive tobacco-control programs have more rapid
decreases in lung cancer than states without such pro-
grams.130,131 Althoughmuch can be learned from the pol-
icy and program strategies used in comprehensive tobacco
control, expanded current research is needed on the im-
portance of lifestyle behaviors, particularly physical inac-
tivity, poor diet, and obesity, to cancer risk and
survival.132-134 Extensive behavioral research, including
randomized controlled trials, has demonstrated that indi-
vidually focused behavioral interventions result in recom-
mended changes in these health behaviors. However, a
key challenge is to identify what is needed to ensure that
these behavioral changes are sustained. Research has iden-
tified that changes in the environments and policies that
support recommended health behaviors are important to
achieve and sustain beneficial lifestyle behaviors. Being
overweight and failing to exercise are adverse trends that
appear to increase risk for CRC,89-92 especially colon can-
cer.95,96,98,135 An estimated 33% of US adults are over-
weight, and another 34% are obese.103 Increasing CRC
incidence among young adults (aged <50 years) may be
an early indicator of the adverse impact of these risk
factors. The CDC recently published policy and commu-
nication strategies to decrease obesity and physical inactiv-
ity,103 including recommended policies to facilitate better
nutrition and environments conducive to physical activ-
ities such as walking or biking. In 2009, a Weight of the
Nation conference136 addressed the need for multiple
approaches to curbing obesity-related illness137 and con-
taining the rising cost of obesity for the nation, which was
estimated at $147 billion in 2007.138
Several risk factors associated with cancer appear to
act over a long time, although some changes in risk factors
can impact cancer incidence in a shorter period of time.
One example is the decline in breast cancer in 2002 after
lower use of combined hormone therapy among
women.139-141 Beyond risk factor reduction, chemopre-
vention is a growing research area, especially because sev-
eral medications used for other purposes appear to be
protective against CRC; however, some substances such as
aspirin have adverse side effects, so additional research is
needed to clarify the effectiveness, appropriate dose, and
potential toxicity of potential chemopreventive thera-
pies.110-112 Recent concerns also are focused on an
increased risk of CRC142 from nationwide fortification of
cereal grains with folic acid in the late 1990s to reduce
neural tube birth defects.
Disparities in cancer incidence and mortality need
further investigation, including ways to decrease
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disparities related to race or ethnicity, socioeconomic sta-
tus, insurance status, geographic location, and access to
healthcare. Eliminating these disparities will require
increased access to screening and advanced treatment
modalities, which place demands on healthcare delivery
systems. Short-term and long-term impact on the health-
care provider workforce, facilities and technology, and
financial resources for cancer interventions to improve
health outcomes for all segments of the population must
be considered. Modifiable risk factors have been identified
(eg, obesity, poor diet, alcohol consumption, and lack of
physical activity) that require effective culturally sensitive
interventions targeting specific populations to reduce
these risk factors.
CRC has been the highlight of this report.
Although great progress has been made in reducing the
impact of CRC, improved application of currently
available knowledge and ongoing research are needed to
make further inroads. CRC research priorities were
established by the NCI Progress Review Group and
have guided a decade of activities, including biologic
and etiologic research in CRC.143 Genome-wide associ-
ation studies recently have implicated multiple loci
across the genome that may contribute to CRC
susceptibility.144
Research also is needed to enhance screening tech-
nologies as well as strategies to increase screening and early
detection; such strategies include community and agency
collaborations to implement screening,145 enhanced
screening in primary care settings and rural areas,146 and
removal of cultural and language barriers to screening.146
Screening has increased considerably since 2000, yet only
approximately 50% of adults aged 50 years were
screened in 2005.71 Studies have suggested possible rea-
sons for less-than-optimal use of CRC screening, includ-
ing variability in physicians’ interpretation and use of
CRC screening guidelines80; lack of insurance coverage,
regular health provider, or awareness71; and a slight
increase in adverse events associated with colonoscopy as
the age of screened patients increases.81 The CDC’s new
Colorectal Cancer Control program will provide direct
screening services to populations at greatest need and will
focus attention on increasing CRC screening rates among
the US population aged 50 years nationwide (available
at: www.cdc.gov/cancer/colorectal and www.cdc.gov/
screenforlife accessed on October 6, 2009).
Several public, private, and voluntary organizations
have targeted CRC screening as one of their most impor-
tant cancer-control priorities and have been working to
educate the public and medical providers concerning the
importance of screening.147 Advocacy efforts at the state
and federal levels have encouraged state legislation requir-
ing coverage for the full range of CRC screening tests and
the development of federal programs to enhance access to
screening and treatment of medically underserved popula-
tions. A state-of-the-science conference hosted by the
NIH in 2010 will focus on ways to enhance the use and
quality of CRC screening.148 Also, a CDC-CISNET col-
laboration is working to assess the capacity of the US
healthcare system to increase CRC screening of individu-
als ages 50-64 years and to determine cost implications for
Medicare, Medicaid, and private payors, taking into con-
sideration increased costs for early detection yet savings in
treatment costs.
Researchers also have made great strides in develop-
ing treatment regimens to optimize patient response and
performance, particularly for patients with metastatic
CRC. Some treatments that have positively impacted
morbidity, quality of life, and survival for CRC patients
include multimodality therapy for rectal cancer and the
use of surgical approaches that result in higher rates of
sphincter preservation.149 Also, surgical resection of he-
patic metastases and, more recently, the development of
new chemotherapies appear to increase survival for
patients with metastatic disease.150,151 Targeted therapies
with monoclonal antibodies have been developed152 as
well as more individualized CRC therapies based on
genetic characteristics of the patient’s tumor.153 A CRC
patient’s survival and quality of life depend on treatment
decisions, and improved treatments and optimal combi-
nation of therapies continue to be goals.154 Some patients
do not tolerate chemotherapy well, and enhanced quality-
of-life research is needed for CRC patients, including pal-
liative care. Best practices for treatments based on a
patient’s needs, staging, preferences, and performance sta-
tus (response to chemotherapy) need to be promoted and
adopted. Research into treatment options that result in
even small gains in CRC patient survival and performance
requires large clinical trials before the treatment can be
made available for general use,154 so ways to facilitate can-
cer drug approval also are needed.155
Disparities exist for CRC as well. Men have higher
rates than women, and black individuals have higher rates
than other racial/ethnic groups. Geographic disparities
also have been reported and may be influenced by access
to healthcare and screening (in low-poverty areas) and by
lifestyle factors (in high-poverty and urban areas).116,156
Studies also indicate that black patients with CRC are
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diagnosed more often at late stages and less often receive
standard therapies than white patients157; they also have
less follow-up surveillance158 and poorer survival rates.159
More research is needed regarding the systemic, clinical,
social, cultural, biologic, environmental, and behavioral
factors that influence CRC incidence, mortality, and
disparities.
Although much progress can be achieved by apply-
ing better what we already know about cancer causation,
prevention, and treatment (eg, tobacco control, vaccina-
tion for human papillomavirus, chemoprevention of
breast cancer in high-risk groups), more research is needed
across the spectrum of cancers in all areas: prevention,
early detection, treatment, and palliation. Further etiolo-
gic research is needed for particularly lethal cancer sites
(eg, pancreatic), those with unexplained increased inci-
dence (ie, cancers of the thyroid, liver, pancreas, kidney,
and melanoma) (Table 4), and cancers for which limited
progress has been made. Extensive research efforts also are
needed to develop personalized/targeted cancer therapies
that involve a better understanding of the genetic and epi-
genetic changes that occur in cells during progression to
cancer, the molecular composition of cancer subtypes,
gene expression, and proteomics.160-163 A combination of
policy, healthcare service delivery, communication, and
engineering and technology interventions can further
reduce the impact of cancer.
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